RScottWrightMDFACC, FAHA, FESC

Professor, Cardiology and Internal Medicine, Mayo Medical School and Mayo Clinic, Director of Human Research Protection, Mayo Clinic, Senior Chair, Mayo Clinic IRB

Join to view full profile

Dr. Wright is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wright's full profile

Already have an account?

Office
200 1st Street SW
Rochester, MN 55905

Summary

I am an academic cardiologist with multiple job responsibilities including academic clinical cardiology, working as a clinical trialist, providing consultative cardiology services and administrative leadership.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Cardiovascular Disease, 1992 - 1996
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1989 - 1992
University of Kentucky College of MedicineClass of 1989

Certifications & Licensure

IA State Medical License 1991 - 2026
MN State Medical License 1990 - 2025
WI State Medical License 1992 - 2025
American Board of Internal Medicine Cardiovascular Disease

Clinical Trials

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease Start of enrollment: 2010 Jan 01
Terminated
Phase 3
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease Start of enrollment: 2012 Jan 01
Completed
Phase 3
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects Start of enrollment: 2013 Oct 29
Terminated
Phase 3
A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C) Start of enrollment: 2014 Dec 01
Completed
Phase 1
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS Start of enrollment: 2016 Apr 01
Completed
Phase 3
A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH) Start of enrollment: 2016 Dec 13
Completed
Phase 2
An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol Start of enrollment: 2017 Apr 27
Completed
Phase 2
A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7) Start of enrollment: 2017 Jun 22
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

The Safety Profile of COVID-19 Convalescent Plasma.
Michael J Joyner, Rickey E Carter, R Scott Wright, Jonathon W Senefeld
Current Topics in Microbiology and Immunology. 2024-12-19
Lipoprotein (a): Underrecognized Risk with a Promising Future.
Matteo Manzato, R Scott Wright, Allan S Jaffe, Vlad C Vasile
Reviews in Cardiovascular Medicine. 2024-11-01
7 citations
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.
R Scott Wright, Frederick J Raal, Wolfgang Koenig, Ulf Landmesser, Lawrence A Leiter
Cardiovascular Research. 2024-10-14

Committees

member, 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
member, 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)
member, ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction—Executive Summary